Macrocyclic compounds as trk kinase inhibitors

摘要

Disclosed herein are macrocyclic compounds of formula (I), wherein the variables ring A, ring B, W, m, D, R2, R2a, R3, R3a, and Z are as defined in the specification. These compounds exhibit Trk family protein tyrosine kinase inhibition and are intended for use in the treatment of pain, cancer, inflammation, neurodegenerative diseases and certain infectious diseases. Also disclosed is a process for the preparation of the compounds of formula I. Specific examples of the compounds of formula I include (6R)-9-fluoro-2,11,15,19,20,23-hexaazapentacyclo[15.5.2.17,11.02,6.020,24]pentacosa-1(23),7,9,17(24),18,21-hexaene-16,25-dione and (4R,6R,15R)-9-fluoro-4,15-dihydroxy-13-oxa-2,17,21,22,25-pentaazapentacyclo[17.5.2.02,6.07,12.022,26]hexacosa-1(25),7(12),8,10,19(26),20,23-heptaen-18-one.